secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031335
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M
--------------------------------------------------------------------------------

- Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.
- Net loss $1.4M ($0.04 loss per diluted share) vs net income $11.5M in Q3 2021.
- Adjusted EBITDA loss $4.1M; cash, equivalents, and marketable securities $86.5M.
- Repurchased 2.9M shares at avg $3.61; generated $1.1M operating cash flow in Q3.
- Co-Dx PCR Home platform nearing clinical evaluations; shipped Monkeypox test and appointed new CSO Dr. Mark Poritz.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/0001493152-22-031335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer